- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03193463
Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan into your brain tumor. A second purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan into your brain tumor.
This study will also determine the best dose of topotecan to deliver to your tumor with use of the Cleveland Multiport Catheter and will also examine how your tumor responds to treatment with topotecan.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Primary Objectives
- To investigate by MR imaging the spatial and temporal distribution of topotecan in enhancing or nonenhancing bulk tumor administered by convection-enhanced delivery (CED) in patients with recurrent/progressive WHO grade III or IV (high grade) glioma (HGG) who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.
- To investigate by MR imaging the influence of the rate and topotecan concentration, on the spatial and temporal distribution of topotecan administered by CED in patients with with recurrent/progressive HGG
Secondary Objectives
- To investigate the extent to which backflow may be observed on MRI during CEDmediated delivery of topotecan
- To assess the safety, tolerability and toxicity profile of topotecan administered by CED using different doses and infusion rates.
- To observe evidence of activity of single-agent topotecan administered by CED to patients with recurrent/progressive HGG who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.
Studietyp
Fas
- Tidig fas 1
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression
- Karnofsky Performance Status 70-100
- MRI demonstration of a stereotactically accessible enhancing mass that does not require resection to relieve clinically significant mass effect
- Patient understands the procedures and agrees to comply with the study requirements by providing written informed consent
Laboratory values within the following ranges:
- Absolute neutrophil count (ANC) ≥ 1,500 / μL
- Platelet count ≥ 100,000 / μL
- Hemoglobin ≥ 10 g / dL
- prothrombin time (PT) / partial thromboplastin time (PTT) not above institutional norms
- Estimated glomerular filtration rate (eGFR) of at least 50 mL/min
Exclusion Criteria:
- Patient is mentally or legally incapacitated at the time of the study
- Known HIV(+) or has been diagnosed with AIDS
- Participation in another investigational drug study in the prior 4 weeks
- Positive pregnancy test in a female
- Patient, in the opinion of the investigator, is likely to be poorly compliant
- Diffuse subependymal or cerebrospinal fluid (CSF) disease
- Tumors involving the cerebellum
- Tumor enhancement involving both hemispheres
- Active infection requiring treatment
- Unexplained febrile illness
- Radiation or chemotherapy within 4 weeks of enrollment
- Systemic diseases associated with unacceptable anesthesia or operative risk
- Inability to undergo magnetic resonance imaging
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Predominantly enhancing mass with volume of 8 cc or less
Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room.
Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage.
The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging.
The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent.
Following completion of the 4-hour infusion, the CMC will be removed.
The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
|
In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
Andra namn:
an investigational device, will be used to deliver the topotecan
to monitor the infusion of topotecan into the tumor
|
Experimentell: Predominantly enhancing mass with volume of > 8 cc
2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter).
The rate used for the second 24 hours of the infusion will be 1.668 ml/hour.
If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour.
Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
|
an investigational device, will be used to deliver the topotecan
to monitor the infusion of topotecan into the tumor
In predominantly enhancing mass with a volume of > 8 cc of topotecan administered.
Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
Andra namn:
|
Experimentell: Predominantly non-enhancing mass
The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour.
The rate used for the second 24 hours of the infusion will be 0.58 ml/hour.
If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour.
Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
|
an investigational device, will be used to deliver the topotecan
to monitor the infusion of topotecan into the tumor
Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of intra-operative catheter related complications
Tidsram: Up to 12 months
|
Documentation of possible, probable, or definite catheter-related complications
|
Up to 12 months
|
Number of post-operative catheter related complications
Tidsram: Up to 12 months
|
Documentation of possible, probable, or definite catheter-related complications
|
Up to 12 months
|
Number of catheter related complications after catheter removal
Tidsram: Up to 12 months
|
Documentation of possible, probable, or definite catheter-related complications
|
Up to 12 months
|
Change in the spatial distribution of intratumorally-administered topotecan at serial timepoints using a gadolinium-based contrast agent, as determined by MRI scan
Tidsram: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion rate, as determined by MRI scan
Tidsram: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using volumetric magnetic resonance imaging, as determined by MRI scan
Tidsram: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using three-dimensional image reconstruction, as determined by MRI scan
Tidsram: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion concentration, as determined by MRI scan
Tidsram: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion duration, as determined by MRI scan
Tidsram: Up to 12 months
|
Up to 12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants with response as measured by the Response Assessment in Neuro-Oncology (RANO) Criteria
Tidsram: Up to 12 months
|
Response includes objective response rate (ORR), median progression-free survival (PFS), proportion progression-free at six months (PFS-6), and median overall survival (OS)
|
Up to 12 months
|
Safety as measured by the common terminology criteria for adverse events (CTCAE)
Tidsram: Up to 12 months
|
Safety will be determined through adverse events by arm
|
Up to 12 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Michael A. Vogelbaum, MD, PhD, Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer, körtel och epitel
- Neoplasmer, neuroepitelial
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Gliom
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Topoisomerasinhibitorer
- Topoisomeras I-hämmare
- Topotecan
Andra studie-ID-nummer
- INFT1317
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Gliom
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationHar inte rekryterat ännuGliom | Låggradigt Gliom | Gliom, elakartad | Låggradigt gliom i hjärnan | Gliom intrakranielltFörenta staterna
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRekryteringGliom | Höggradig Gliom | Gliom, elakartad | Diffus gliom | Gliom intrakranielltFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Aktiv, inte rekryterandeÅterkommande glioblastom | Återkommande malignt gliom | Refraktärt malignt gliom | Återkommande WHO Grad III Gliom | Återkommande WHO Grad II Gliom | Refraktär glioblastom | Refraktär WHO Grade II Gliom | Refraktär WHO Grad III GliomFörenta staterna
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRekryteringGlioblastom | Malignt gliom | Återkommande glioblastom | Återkommande WHO Grad III Gliom | WHO Grad III Gliom | IDH2-genmutation | IDH1-genmutation | Låggradig gliom | Återkommande WHO Grad II Gliom | WHO Grad II GliomFörenta staterna
-
National Cancer Institute (NCI)RekryteringGliom | Höggradig Gliom | Malignt gliom | Gliomas | Låggradig gliomFörenta staterna
-
Hospital del Río HortegaAvslutadGliom | Glioblastom | Låggradigt Gliom | Gliom, elakartad | Högkvalitativ GliomSpanien
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeGlioblastom | Malignt gliom | WHO Grad III Gliom | Återkommande Gliom | Eldfast GliomFörenta staterna
-
Beijing Tiantan HospitalDuke UniversityOkändGlioblastom | Höggradig Gliom | Gliom, elakartad | Gliom av hjärnstammenKina
-
SanofiAvslutadGlioblastoma Multiforme | Maligna gliom | Blandade gliomFörenta staterna
-
ChimerixAktiv, inte rekryterandeGlioblastom | Diffus mittlinjegliom | H3 K27M Gliom | Thalamisk gliom | Infratentoriellt gliom | Basal Ganglia GliomFörenta staterna
Kliniska prövningar på Topotecan (<=8cc)
-
Xian-Janssen Pharmaceutical Ltd.Avslutad
-
Spectrum Pharmaceuticals, IncAvslutadSmåcellig lungcancer | Äggstockscancer | Fasta tumörerFörenta staterna
-
Fujifilm Pharmaceuticals U.S.A., Inc.RekryteringAvancerade solida tumörerFörenta staterna
-
Centre Francois BaclesseGlaxoSmithKline; Centre d'Etudes et de Recherche pour l'Intensification...AvslutadCancer | Kemoterapi | Återfall | OvarialFrankrike
-
St. Jude Children's Research HospitalGlaxoSmithKline; National Institutes of Health (NIH)AvslutadWilms tumörFörenta staterna, Kanada
-
Katy PetersGlaxoSmithKline; Schering-PloughAvslutadGlioblastom | Gliosarkom | Anaplastiskt astrocytomFörenta staterna
-
Montefiore Medical CenterSanofi; GlaxoSmithKlineAvslutadUterina neoplasmer | Ovariella neoplasmerFörenta staterna
-
Gustave Roussy, Cancer Campus, Grand ParisErasmus Medical Center; Catholic University of the Sacred Heart; St. Anna...AvslutadNeuroblastom | Fasta tumörer | HjärntumörerFrankrike
-
Taiho Oncology, Inc.Taiho Pharmaceutical Co., Ltd.AvslutadSmåcellig lungcancer (SCLC)Japan, Italien, Tyskland
-
The Hospital for Sick ChildrenRekrytering